IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

Vaccine

Volumn 24, Issue 26, 2006, Pages 5461-5472

  Schellack, Carola ^a   Prinz, Karin ^a   Egyed, Alena ^a   Fritz, Jörg H ^b   Wittmann, Barbara ^a   Ginzler, Michael ^a   Swatosch, Gabriele ^a   Zauner, Wolfgang ^a   Kast, Constantia ^a   Akira, Shizuo ^c   von Gabain, Alexander ^a   Buschle, Michael ^a   Lingnau, Karen ^a  

^a INTERCELL AG   (Austria)

^b INSTITUT PASTEUR   (France)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Antibodies; CTL; Vaccine

Indexed keywords

DEOXYCYTIDINE PHOSPHATE; DEOXYINOSINE; GAMMA INTERFERON; IC31; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYNUCLEOTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; FEMALE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

EID: 33744806358     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.071     Document Type: Article

References (32)

1. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 7 (2001) 388
2. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12 (2000) 456
3. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 17 (1999) 1075
4. Eriksson K., and Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14 (2002) 666
5. Cox J.C., and Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine 15 (1997) 248
6. Kenney R.T., and Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2 (2003) 167
7. Oppenheim J.J., Biragyn A., Kwak L.W., and Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 62 Suppl 2 (2003) ii17
8. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740
9. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732
10. Lipford G.B., Sparwasser T., Bauer M., Zimmermann S., Koch E.S., Heeg K., et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 27 (1997) 3420
11. Sparwasser T., Miethke T., Lipford G., Borschert K., Hacker H., Heeg K., et al. Bacterial DNA causes septic shock. Nature 386 (1997) 336
12. Monteith D.K., Henry S.P., Howard R.B., Flournoy S., Levin A.A., Bennett C.F., et al. Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12 (1997) 421
13. Schmidt W., Buschle M., Zauner W., Kirlappos H., Mechtler K., Trska B., et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 94 (1997) 3262
14. Mattner F., Fleitmann J.K., Lingnau K., Schmidt W., Egyed A., Fritz J., et al. Vaccination with poly-l-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 62 (2002) 1477
15. Buschle M., Schmidt W., Zauner W., Mechtler K., Trska B., Kirlappos H., et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc Natl Acad Sci USA 94 (1997) 3256
16. Lingnau K., Egyed A., Schellack C., Mattner F., Buschle M., and Schmidt W. Poly-l-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20 (2002) 3498
17. Lipford G.B., Heeg K., and Wagner H. Bacterial DNA as immune cell activator. Trends Microbiol 6 (1998) 496
18. Krieg A.M., Yi A.K., Schorr J., and Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6 (1998) 23
19. Bauer M., Redecke V., Ellwart J.W., Scherer B., Kremer J.P., Wagner H., et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol 166 (2001) 5000
20. Barton G.M., and Medzhitov R. Toll-like receptor signaling pathways. Science 300 (2003) 1524
21. Martin R.M., Brady J.L., and Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212 (1998) 187
22. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 (1992) 1693
23. Oehen S., and Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 161 (1998) 5338
24. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nature Rev Immunol 2 (2002) 151
25. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
26. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
27. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin Immunol 12 (2000) 163
28. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
29. Cho J.H., Homma K., Kanegasaki S., and Natori S. Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLKLK-NH2, via cell surface calreticulin. Eur J Biochem 266 (1999) 878
30. Schijns V.E. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21 (2003) 829
31. Heath W.R., and Carbone F.R. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1 (2001) 126
32. Fritz J.H., Brunner S., Birnstiel M.L., Buschle M., von Gabain A., Mattner F., et al. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a Th2-type immune response to co-injected antigens. Vaccine 22 (2004) 3274